Jim Simons acquired 315 Thousand Intra-Cellular Therapies shares worth $41.5 Million. That's 0.06% of their equity portfolio (359th largest holding). The first Intra-Cellular Therapies trade was made in Q1 2015. Since then Jim Simons bought shares eleven more times and sold shares on fourteen occasions. The stake costed the investor $21.5 Million, netting the investor a gain of 92% so far.